Please try another search
BiVictriX Therapeutics plc is a United Kingdom-based drug discovery and development company focused on developing cancer therapeutics. The Company’s lead program, BVX001, is a Bi-Cygni antibody drug conjugate (ADC) designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with acute myeloid leukemia (AML), and in subpopulations of cancer cells from patients with other hematological cancers. The Company generates a pipeline of Bi-Cygni ADC therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints on tumor cells, which are largely absent from healthy cells. It has established a library of cancer-specific Bi-Cygni fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilizes these Bi-Cygni fingerprints, together with the Company’s ADC therapeutic design, to develop therapeutics to target cancers.
Name | Age | Since | Title |
---|---|---|---|
Robert Edward Hawkins | 67 | 2021 | Independent Non-Executive Director |
Michael Glen Kauffman | 60 | 2022 | Non-Executive Chairman |
William Drummond Paris | 71 | 2021 | Senior Independent Non-Executive Director |
Tiffany Jane Thorn | 35 | 2018 | CEO & Executive Director |
Susan Day Lowther | 63 | 2021 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review